Skip to main content

Search

Show all results for

Home

Person

Daniel Kenneth Bonner

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (3)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses

Jeffrey Alan Hubbell, Melody Swartz, Sachiko Hirosue, Alexandre de Titta, Daniel Kenneth Bonner

Background: Newborns display distinct immune responses, leaving them vulnerable to infections and impairing immunization. Targeting newborn dendritic cells (DCs), which integrate vaccine signals into adaptive immune responses, might enable development of a ...

2017

A Cationic Micelle Complex Improves CD8+T Cell Responses in Vaccination Against Unmodified Protein Antigen

Jeffrey Alan Hubbell, Davide Demurtas, Melody Swartz, Carrie Ellen Brubaker, Daniel Kenneth Bonner, Vasiliki Panagiotou

Nanoscale carrier platforms promote immune responses to vaccination by facilitating delivery of vaccine components to immunologically relevant sites. The technique is particularly valuable for subunit vaccination, in which coadministration of immunostimula ...

Amer Chemical Soc2016

Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses

Jeffrey Alan Hubbell, Marcela Rincón-Restrepo, Melody Swartz, Sachiko Hirosue, Edward Allen Phelps, Sylvie Hauert, Daniel Kenneth Bonner, Aaron Mayer

Nanoparticle delivery systems are known to enhance the immune response to soluble antigens (Ags) and are thus a promising tool for the development of new vaccines. Our laboratory has engineered two different nanoparticulate systems in which Ag is either en ...

Elsevier Sci Ltd2017